BMN 333

DRUG2 trials

Sponsors

Biomarin Pharmaceutical Inc., BioMarin Pharmaceutical

Conditions

Achondroplasia

Phase 2

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

RecruitingNCT07441876

BioMarin PharmaceuticalAchondroplasia

Start: 2026-04-01End: 2029-09-01Target: 160Updated: 2026-05-07

A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia

Not yet recruitingCTIS2025-523811-12-00

Biomarin Pharmaceutical Inc.Achondroplasia

Target: 25Updated: 2026-05-05